Previous 10 | Next 10 |
Treatment with OCA resulted in early and sustained improvements of commercially available noninvasive biomarker and imaging assessments of fibrosis Additional patient-reported outcomes data demonstrate that pruritus in patients treated with OCA 25 mg did not have an impact on measures...
Image source: The Motley Fool. Intercept Pharmaceuticals Inc (NASDAQ: ICPT) Q3 2019 Earnings Call Nov 5, 2019 , 8:30 a.m. ET Operator Continue reading
Intercept Pharmaceuticals, Inc. (ICPT) Q3 2019 Earnings Conference Call November 05, 2019 08:30 AM ET Company Participants Lisa DeFrancesco - Vice President, Investor Relations Mark Pruzanski - Chief Executive Officer Jerry Durso - Chief Operating Officer Sandip Kapadia - Chief...
The following slide deck was published by Intercept Pharmaceuticals, Inc. in conjunction with their 2019 Q3 earnings Read more ...
Intercept Pharma (NASDAQ: ICPT ): Q3 GAAP EPS of -$2.59 misses by $0.19 . Revenue of $61.95M (+32.1% Y/Y) misses by $1.58M . Shares +0.2% PM. Press Release More news on: Intercept Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
Worldwide Ocaliva net sales of $61.5 million in the third quarter of 2019 representing 32% growth versus the prior year quarter; increasing full year 2019 worldwide Ocaliva net sales guidance range to between $245 million and $250 million U.S. NDA for NASH submitted; EU MAA submiss...
AFI , AGN , AMRC , AMRN , ARNC , ASC , ATH , ATHM , ATRO , AVNS , AVTR , BCPC , BDX , BMCH , BPMC , CEIX , CHH , CHK , CNK , CSWI , CTLT , EMR , ENDP , EQM , EXPD , FI , FIS , FTDR , GEO , GLDD , GSKY , GSX , HLNE , HSIC , ICPT , IPI , JLL , LAMR , LCI...
NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2019 financial results...
New analyses from Phase 3 REGENERATE study evaluating the effects of OCA on non-invasive liver fibrosis tests and NASH patient-reported outcomes Five-year analysis of long-term Ocaliva ® treatment in patients with PBC selected for inclusion in ‘Best of the Liver Meeting...
The American Association of Liver Diseases Annual Meeting, better known as The Liver Meeting, will open in Boston on Nov. 8. Data will be presented on new therapies for diseases ranging from hepatitis to non-alcoholic steatohepatitis (NASH), which affect hundreds of thousands, if not millions, o...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...